Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
07 Novembre 2024 - 2:30PM
Business Wire
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a
social innovation platform dedicated to accelerating promising
health innovations, today shared an important milestone for its
target acquisition, Appili Therapeutics Inc. (TSX: APLI; OTCPink:
APLIF) (“Appili”). Shareholders of Appili overwhelmingly voted in
favor of a plan of arrangement for Aditxt to acquire all issued and
outstanding Class A common shares of Appili. For additional
information and results of Appili’s special meeting of
shareholders, please visit this link.
About Appili Therapeutics
Appili Therapeutics is an infectious disease biopharmaceutical
company that is purposefully built, portfolio-driven, and
people-focused to fulfill its mission of solving life-threatening
infections. Appili aims to strategically develop a pipeline of
novel therapies to prevent deaths and improve lives by
systematically identifying urgent infections with unmet needs. The
Company is currently advancing a diverse range of anti-infectives,
including an FDA-approved ready-made suspension of metronidazole
for the treatment of antimicrobial infections, a vaccine candidate
to eliminate a severe biological weapon threat, and a topical
antiparasitic for the treatment of a disfiguring disease. Appili is
at the epicenter of the global fight against infection, led by a
proven management team. For more information, visit
www.AppiliTherapeutics.com.
About Aditxt, Inc.
Aditxt, Inc.® is a social innovation platform dedicated to
accelerating promising health innovations. Aditxt’s ecosystem of
research institutions, industry partners, and shareholders
collaboratively drives their mission to "Make Promising Innovations
Possible Together." The innovation platform is the cornerstone of
Aditxt’s strategy, where multiple disciplines drive disruptive
growth and address significant societal challenges. Aditxt operates
a unique model that democratizes innovation, ensures every
stakeholder’s voice is heard and valued, and empowers collective
progress.
Aditxt currently operates two programs focused on immune health
and precision health. The Company plans to introduce two additional
programs dedicated to public health and women’s health. For these,
Aditxt has entered into an Arrangement Agreement with Appili
Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which
focuses on infectious diseases, and a Merger Agreement with Evofem.
Each program will be designed to function autonomously while
collectively advancing Aditxt’s mission of discovering, developing,
and deploying innovative health solutions to tackle some of the
most urgent health challenges. The closing of each of the
transactions with Appili and Evofem is subject to several
conditions, including but not limited to approval of the
transactions by the respective target shareholders and Aditxt
raising sufficient capital to fund its obligations at closing. No
assurance can be provided that all of the conditions to closing
will be obtained or satisfied or that either of the transactions
will ultimately close.
For more information, www.aditxt.com.
Follow us on:
LinkedIn: https://www.linkedin.com/company/aditxt Facebook:
https://www.facebook.com/aditxtplatform/
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of federal
securities laws. Forward-looking statements include statements
regarding the Company’s intentions, beliefs, projections, outlook,
analyses, or current expectations concerning, among other things,
the Company’s ongoing and planned product and business development;
the Company’s ability to finance and execute its strategic M&A
initiatives; the Company’s ability to obtain the necessary funding
and partner to commence clinical trials; the Company’s intellectual
property position; the Company’s ability to develop commercial
functions; expectations regarding product launch and revenue; the
Company’s results of operations, cash needs, spending, financial
condition, liquidity, prospects, growth, and strategies; the
Company’s ability to raise additional capital; the industry in
which the Company operates; and the trends that may affect the
industry or the Company. Forward-looking statements are not
guarantees of future performance, and actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, as well as market and
other conditions and those risks more fully discussed in the
section titled “Risk Factors” in Aditxt’s most recent Annual Report
on Form 10-K, as well as discussions of potential risks,
uncertainties, and other important factors in the Company’s other
filings with the Securities and Exchange Commission. All such
statements speak only as of the date made, and the Company
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20241107621389/en/
Aditxt, Inc. Investors: Jeff
Ramson, PCG Advisory, Inc. T: 646-863-6893
Jramson@pcgadvisory.com
Corporate Communications: Mary O’Brien Mobrien@aditxt.com
Grafico Azioni Appili Therapeutics (TSX:APLI)
Storico
Da Nov 2024 a Dic 2024
Grafico Azioni Appili Therapeutics (TSX:APLI)
Storico
Da Dic 2023 a Dic 2024